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Abstract 
Background: Circadian rhythms regulate key biological processes influencing metabolic pathways. Disregulation 
is associated with type 2 diabetes (T2D) and cardiovascular diseases (CVD). Circadian rhythms are generated by a 
transcriptional autoregulatory feedback loop involving core clock genes. CLOCK (circadian locomotor output cycles 
protein kaput), one of those core genes, is known to regulate glucose metabolism in rodent models. Cross‑sectional 
studies in humans have reported associations between this locus and obesity, plasma glucose, hypertension and T2D 
prevalence, supporting its role in cardiovascular risk. However, no longitudinal study has investigated the associa‑
tion between CLOCK gene variation and T2D or CVD incidence. Moreover, although in a previous work we detected 
a gene‑diet interaction between the CLOCK‑rs4580704 (C > G) single nucleotide polymorphism (SNP) and monoun‑
saturated (MUFA) intake on insulin resistance, no interventional study has analyzed gene‑diet interactions on T2D or 
CVD outcomes.
Methods: We analyzed the association between the CLOCK‑rs4580704 SNP and incidence of T2D and CVD longitu‑
dinally in 7098 PREDIMED trial (ISRCTN35739639) participants after a median 4.8‑year follow‑up. We also examined 
modulation by Mediterranean diet (MedDiet) intervention (high in MUFA) on these associations.
Results: We observed a significant association between the CLOCK‑rs4580704 SNP and T2D incidence in n = 3671 
non‑T2D PREDIMED participants, with variant allele (G) carriers showing decreased incidence (dominant model) com‑
pared with CC homozygotes (HR: 0.69; 95 % CI 0.54–0.87; P = 0.002). This protection was more significant in the Med‑
Diet intervention group (HR: 0.58; 95 % CI 0.43–0.78; P < 0.001) than in the control group (HR: 0.95; 95 % CI 0.63–1.44; 
P = 0.818). Moreover, we detected a statistically significant interaction (P = 0.018) between CLOCK‑rs4580704 SNP and 
T2D status on stroke. Thus, only in T2D subjects was CLOCK‑rs4580704 SNP associated with stroke risk, G‑carriers hav‑
ing decreased risk (HR: 0.61; 95 % CI 0.40–0.94; P = 0.024 versus CC) in the multivariable‑adjusted model.
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Background
The continued increase in the incidence of type 2 dia-
betes (T2D) has elicited the need to investigate in more 
depth and breadth the risk factors that contribute to this 
disease in order to have a more comprehensive vision of 
the process to illuminate the path towards more precise 
and effective preventive interventions [1–3]. In addition, 
and given the impact of T2D on cardiovascular diseases 
(CVD) [2, 4–8] we need to gain further knowledge about 
the factors driving the connection between T2D and 
CVD. In this regard, there is increasing evidence linking 
chronodisruption with metabolic disorders [9–12].
All living things have acquired, in the course of evolu-
tion, an internal circadian timing system so as to adapt 
to the rhythmically occurring daily changes in their 
environment [13, 14]. In humans, this circadian timing 
coordinates virtually all physiological processes encom-
passing the states of sleep and wakefulness, endocrine 
functions and cardiovascular activity [15, 17]. It has been 
shown that several aspects of the cardiovascular physi-
opathology and incidence of CVD events, such as myo-
cardial infarction, ischemic and hemorrhagic stroke, have 
diurnal variation, peaking in the early morning hours 
[18–23]. Moreover, a higher risk of obesity, metabolic 
alterations and T2D has been found in shift workers [24–
27] and adverse cardiometabolic effects (including post-
prandial glucose in a range typical of a prediabetes state) 
have been detected in subjects who underwent forced 
circadian misalignment [28].
The endogenous circadian timing system includes the 
suprachiasmatic nucleus (SNC) in the hypothalamus, as 
well as peripheral oscillators in the different organs [29]. 
The core molecular clock is composed of a transcrip-
tion-translation feedback loop that oscillates with 24-h 
rhythmicity [30]. Several core clock genes are involved in 
the regulation of this system [14, 30]. Among them, the 
CLOCK (Circadian Locomotor Output Cycles Kaput) 
gene, a transcription factors from the positive limb of 
the molecular clock that forms a complex with BMAL1 
(Brain and Muscle ARNT-Like 1), is one of the most rel-
evant [14, 30, 31]. In murine models, mutations in the 
clock gene were first associated with glucose homeostasis 
[32] and later with obesity, hyperglycemia and hyperinsu-
linemia [33]. In humans, various CLOCK single nucleo-
tide polymorphisms (SNPs) (i.e. rs1464490, rs3749474, 
rs4864584, rs4580704 and rs18012602) have also been 
associated with obesity [34–36], hyperglycemia and 
greater prevalence of T2D in cross-sectional studies [36, 
37]. However, there has been no longitudinal study to 
analyze the influence of CLOCK SNPs on T2D incidence. 
The CLOCK-rs4580704 C > G, a tag SNP in linkage dis-
equilibrium with other CLOCK SNPs, is one of the most 
relevant SNPs for these associations [35, 36]. In our pre-
vious work in the Genetics of Lipid Lowering Drugs and 
Diet Network (GOLDN) population, we observed that 
carriers of the minor allele (G) for the CLOCK-rs4580704 
SNP presented lower weight, fasting-insulin and hyper-
glycemia risk [36].
Moreover, we detected a gene-diet interaction between 
the CLOCK-rs4580704 SNP and monounsaturated fatty 
acids (MUFA) intake in determining fasting glucose and 
insulin resistance in GOLDN [36]. When the MUFA 
intake was low, no differences were found for these 
parameters. However, when MUFA intake was high, 
minor allele carriers had significantly lower levels. We 
also suggested that this SNP could be relevant in modu-
lating CVD risk [36]. However, the latter connection has 
not been specifically investigated. Bearing in mind that 
there may be a greater alteration in circadian rhythms 
in T2D [9–11, 16], we hypothesized that the effect of 
variation in clock genes on CVD risk might be greater in 
T2D subjects. Our aims, therefore, were as follows: (1) 
to analyze the association between the tag SNP CLOCK-
rs4580704 and the incidence of T2D; (2) to analyze the 
association between the CLOCK-rs4580704 SNP and 
incidence of clinical CVD events depending on T2D sta-
tus and; (3) to study whether a dietary intervention with 
the Mediterranean diet (MedDiet), very high in MUFA, 
within the framework of the PREDIMED trial, modulates 
these associations.
Methods
The present study was conducted within the framework 
of the PREvención con DIeta MEditerránea (PRED-
IMED) trial, whose design has been described in detail 
elsewhere [38]. Briefly, the PREDIMED study is a large, 
multicenter, randomized and controlled clinical trial 
aimed at assessing the effects of the Mediterranean diet 
(MedDiet) on primary cardiovascular prevention [38, 
39]. This study was registered at controlled-trials.com 
Conclusions: In agreement with our previous results showing a protective effect of the G‑allele against hypergly‑
cemia, we extended our findings by reporting a novel association with lower T2D incidence and also suggesting a 
dietary modulation. Moreover, we report for the first time an association between a CLOCK polymorphism and stroke 
in T2D subjects, suggesting that core clock genes may significantly contribute to increased CVD risk in T2D.
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(http://www.controlledtrials.com/ISRCTN35739639). 
Participants were randomized to one of three interven-
tions: a MedDiet supplemented with extra virgin olive oil 
(EVOO), a MedDiet supplemented with mixed nuts, or 
advice on a low-fat diet (control diet). Here we included 
7098 participants from whom DNA was isolated, the pol-
ymorphism determined, and who had valid data for the 
main clinical variables analyzed. The completion date of 
this study was December 2010 and the total number of ran-
domized subjects was 7447. The 7098 participants included 
in the present study did not differ in the main character-
istics from those of the total cohort. Additional file 1: Fig-
ure S1 shows the CONSORT flowchart of the trial for the 
primary outcomes. Details of the PREDIMED trial includ-
ing sample size calculations and interim analysis have been 
fully described elsewhere [38, 39]. Briefly, From October 
2003 physicians in Primary Care Centers selected high 
cardiovascular risk participants. Eligible were community-
dwelling persons (55–80  years for men; 60–80  years for 
women) who met at least one of two criteria: T2D or 3 or 
more cardiovascular risk factors as previously detailed [38, 
39]. Taking into account that no significant differences in 
CVD incidence were found between the MedDiet groups 
[39], data were analyzed pooling together the MedDiet 
intervention groups versus the control group.
A detailed description of the nutritional interven-
tions has been provided elsewhere [39]. The Institutional 
Review Board/Ethics Committee of each participating 
center approved the study protocol. All participants pro-
vided written informed consent. Participants were fol-
lowed up for a median of 4.8  years (interquartile range 
2.8–5.8  years). Incidence of CVD as primary outcome 
and incidence of T2D in non-T2D participants (as sec-
ondary study outcome) were assessed.
Demographic, clinical, anthropometric and dietary 
measurements
The baseline examination included assessment of stand-
ard cardiovascular risk factors, medication use, socio-
demographic factors and lifestyle variables by validated 
questionnaires [38]. Food consumption was determined 
by a validated semi-quantitative food frequency ques-
tionnaire (FFQ) [40] and energy and nutrient intake was 
derived. For dietary intake obtained by FFQ, n  =  7040 
subjects were analyzed after exclusion of n = 58 subjects 
with invalid data. Adherence to MedDiet at baseline was 
assessed by a validated 14-item questionnaire [41]. Physi-
cal activity was estimated by the Minnesota Leisure-Time 
Physical Activity Questionnaire, as previously reported 
[38].
Weight and height were measured with calibrated 
scales and a wall-mounted stadiometer, respectively. 
BMI and the waist-to-height ratio were calculated. Blood 
pressure and heart rate were measured in triplicate using 
a validated semiautomatic oscillometer (Omron HEM-
705CP, Hoofddorp, The Netherlands) with a 5-minute 
interval between each measurement with the patients 
seated and at rest in a peaceful setting. The means of 
these measurements were calculated. Hypertension was 
defined as having blood pressure ≥140/90  mm Hg or 
treatment with an antihypertensive medication) and dys-
lipidemia was defined as having a high plasma LDL-C 
concentration (≥160 mg/dL or lipid-lowering therapy), a 
low plasma HDL-cholesterol concentration (≤40 in men 
and ≤50 mg/dL in women).
Biochemical determinations, DNA extraction 
and genotyping
At baseline, blood samples were obtained after an over-
night fast. Fasting glucose and lipids were measured as 
previously described [42]. Biochemical data were avail-
able for the following number of participants with valid 
genotype data for the rs4580704 SNP: fasting glucose 
(n = 6716), total cholesterol (n = 6834), HDL cholesterol 
(n = 6753), LDL cholesterol (n = 6698), and triglycerides 
(n  =  6795). Genomic DNA was extracted from buffy-
coat and the CLOCK-rs4580704 (C > G) polymorphism, 
was genotyped on a 7900HT Sequence Detection Sys-
tem (Applied Biosystems, Foster City, CA, USA) using 
a fluorescent allelic discrimination TaqManTM assay 
(n  =  7098 valid genotypes). Genotype frequencies did 
not deviate from Hardy–Weinberg equilibrium expecta-
tions (P = 0.145).
Outcome ascertainment
CVD outcomes
The primary endpoint was the occurrence of the first 
major CVD events and comprised a composite endpoint 
including myocardial infarction, stroke or cardiovascu-
lar death [38, 39]. We used four sources of information 
to identify end-points: (1) repeated contacts with par-
ticipants; (2) family physicians; (3) yearly review of medi-
cal records; and (4) consultation of the National Death 
Index. The end-point adjudication committee, whose 
members were blind to treatment allocation, examined 
all medical records related to end-points. Only end-
points confirmed by the adjudication committee that 
occurred between October 1, 2003, and December 1, 
2010 were included in the analyses (n = 265). The criteria 
for adjudicating primary outcomes are detailed elsewhere 
[39].
T2D outcomes
Clinical diagnosis of prevalent T2D was an inclusion 
criteria of the PREDIMED study as previously reported 
[38], and these subjects (n  =  3427) were considered as 
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prevalent cases of T2D. Incidence of T2D was a pre-spec-
ified secondary outcome of the PREDIMED trial [38]. 
New-onset diabetes during follow-up was diagnosed 
using the American Diabetes Association criteria, namely 
fasting plasma glucose levels ≥7.0 mmol/L (≥126.1 mg/
dL) or 2-hour plasma glucose levels ≥11.1  mmol/L 
(≥200.0 mg/dL) after a 75-g oral glucose load, as previ-
ously reported [43]. A review of all medical records of 
participants was completed yearly in each center by phy-
sician-investigators who were blinded to the intervention. 
When new-onset T2D cases were identified on the basis 
of a medical diagnosis reported in the medical charts or 
on a glucose test during routine biochemical analyses 
(conducted at least once per year), these reports were 
sent to the PREDIMED Clinical Events Committee [38], 
whose members were also blinded to dietary group or 
the CLOCK genotype. All confirmed cases that occurred 
between October 1, 2003 and December 1, 2010 were 
included in the present analysis (n = 286).
Statistical analyses
Data were analyzed at baseline and longitudinally after a 
median of 4.8 y of follow-up. We used ANOVA tests to 
compare the means of the continuous variables at base-
line for the CLOCK-rs4580704 C  >  G genotypes. Asso-
ciation with fasting glucose at baseline was also estimated 
in a dominant model adjusted for covariates. Chi square 
tests were used to test differences in percentages. The 
CLOCK-rs4580704 SNP was first tested as following a 
general genetic model, including the three genotype cat-
egories (the CC genotype was considered the reference 
category) in order to check the model assumptions. After, 
if similar effects for CG and GG subjects were observed, 
dominant models grouping carriers of the variant G-allele 
were analyzed and presented as the selected genetic 
model. Incidence of T2D was estimated in non-T2D par-
ticipants at baseline (n = 3671). To examine the associa-
tion between the polymorphism and T2D incidence in 
non-T2D subjects at baseline, we used Cox regression 
models with the length of follow-up as the primary time 
variable. Follow-up time was calculated from the date of 
enrolment to the date of diagnosis of T2D for cases, and 
to the date of the last visit or the end of the follow-up 
period (December 1, 2010 for non-cases), or the date at 
death, depending on whichever came first. Hazard ratios 
(HR) with 95 % confidence intervals (CI) for the CLOCK-
rs4580704 C  >  G SNP, were computed. Analyses were 
based on the intention-to-treat principle. In multivaria-
ble model 1 (basic model) we adjusted for sex, age, center 
and intervention group. Afterwards an additional control 
for more potential confounders such as BMI, smoking, 
drinking, physical activity, medications (for hypertension, 
dyslipidemia), adherence to the MedDiet and total energy 
intake at baseline (model 2) was carried out. Moreover, to 
analyze the heterogeneity of genetic effects by the dietary 
intervention, we tested the statistical significance of the 
interaction term between the CLOCK-rs4580704 SNP 
(dominant model) and the dietary intervention (subjects 
in the two MedDiet groups were merged in a single cat-
egory (MedDiet group) versus the control group) in the 
multivariable Cox regression model (models 1 and 2). 
Stratified analyses by dietary intervention group (Med-
Diet and control group) were additionally carried out and 
HR and 95 % CI for T2D were estimated in each stratum 
as indicated above. Kaplan–Meier survival curves (cumu-
lative T2D-free survival) were plotted to estimate the 
probability of remaining free of T2D during follow-up 
depending on the CLOCK-rs4580704 genotype.
To examine the association between the CLOCK- 
rs4580704 SNP and CVD in the whole population (non-
T2D and T2D subjects) and by T2D status (at baseline), 
we used Cox regression models with the length of fol-
low-up as the primary time variable. Follow-up time was 
calculated from the date of enrolment to the date of diag-
nosis of CVD for cases, and to the date of the last visit or 
the end of the follow-up period (December 1, 2010 for 
non-cases), or the date at death, depending on whichever 
came first. Hazard ratios (HR) with 95 % confidence inter-
vals (CI) for the CLOCK-rs4580704 SNP, were computed. 
Analyses were based on the intention-to-treat principle. 
In multivariable model 1 (basic model) we adjusted for 
sex, age, center and intervention group. Afterwards an 
additional control for more potential confounders such 
as BMI, smoking, drinking, physical activity, medica-
tions (hypertension, dyslipidemia, hyperglycemia), adher-
ence to the MedDiet and total energy intake at baseline 
(model 2) was carried out as indicated above for T2D. The 
interaction term between diabetes status and the CLOCK-
rs4580704 C > G SNP in determining total CVD (general 
genetic model) and specific causes of CVD (dominant 
model) was tested in the multivariable Cox regression 
model (models 1 and 2). In T2D subjects, we also esti-
mated the association between the CLOCK-rs4580704 
C  >  G SNP and stroke and myocardial infarction using 
multivariable Cox regression models. Additionally, for the 
stroke outcome we tested the potential heterogeneity of 
genetic effect (dominant model) of dietary intervention 
(MedDiet versus control group). Kaplan–Meier survival 
curves for stroke were also plotted. Statistical analyses 
were performed with the IBM SPSS Statistics version 22, 
NY. All tests were two-tailed and P values <0.05 were con-
sidered statistically significant.
Results
Additional file  1: Table S1 shows demographic, clini-
cal, lifestyle and genetic characteristics of the studied 
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population (n = 7098 subjects) at baseline depending on 
dietary intervention group. Prevalence of the CLOCK-
rs4580704 C > G genotypes was as follows: CC (37.6 %), 
CG (48.1  %) and GG (14.3  %). No statistically signifi-
cant differences of genotype prevalence among the die-
tary intervention groups was detected (P =  0.570). The 
minor allele frequency (MAF) for the G-variant allele 
was 0.38. General characteristics of participants by dia-
betes status are presented in Additional file 1: Table S2. 
Table  1 shows demographic, clinical and lifestyle char-
acteristics of the study participants at baseline, depend-
ing on the CLOCK-rs4580704 C > G SNP. We observed 
statistically significant associations of the polymorphism 
with anthropometric variables (weight, BMI and waist 
circumference) at baseline. These parameters were lower 
in homozygous subjects for the variant G-allele. No sta-
tistically significant differences were detected for blood 
pressure, plasma lipid concentrations, fasting glucose, 
physical activity, total energy and macronutrient intake. 
An association was observed for adherence to the Med-
Diet, being slightly higher in carriers of the G-allele and 
this variable was further included in the multivariable 
adjusted model. By T2D status, the most relevant associ-
ation was found with fasting glucose in non-T2D subjects 
Table 1 Demographic, clinical, lifestyle and genetic characteristics of the study participants at baseline according to the 
CLOCK-rs4580704 genotype
Total indicates the maximum number of participants included with genotype data and demographic, anthropometric, adherence to MedDiet, physical activity and 
clinical variables. For dietary intake obtained by food-frequency questionnaires n = 7040 subjects were analyzed after exclusion of n = 58 subjects with invalid data. 
Biochemical data were available for fasting glucose (n = 6716 participants) total cholesterol (n = 6834 participants), HDL cholesterol (n = 6753 participants), LDL 
cholesterol (n = 6698 participants), and triglycerides (n = 6795 participants)
MUFA Monounsaturated fatty acids, MedDiet Mediterranean diet, EVOO extra virgin olive oil
a Based on a 14-point screener of adherence
1  P unadjusted P-value obtained in the ANOVA test
CC (n = 2667) CG (n = 3415) GG (n = 1016) P1
Age (years) 66.9 (6.2) 67.0 (6.2) 67.0 (6.3) 0.961
Weight (Kg) 76.9 (12.0) 77.1 (12.1) 75.4 (11.5) <0.001
BMI (Kg/m2) 30.0 (3.8) 30.0 (3.9) 29.7 (3.8) 0.030
Waist circumference (cm) 100.5 (10.3) 100.6 (10.9) 99.3 (10.3) 0.002
Female sex n,  % 1551 (58.2) 1932 (56.6) 587 (57.8) 0.444
Current smokers n,  % 365 (13.7) 494 (14.5) 143 (14.1) 0.399
T2D prevalence n,  % 1314 (49.3) 1616 (47.3) 497 (48.9) 0.291
CLOCK‑rs4580704 n,  % 0.570
 MedDiet with EVOO 901 (33.8) 1208 (35.4) 339 (33.4)
 MedDiet with nuts 927 (34.8) 1078 (31.6) 328 (32.3)
 Control 839 (31.5) 1129 (33.1) 349 (34.4)
SBP (mm Hg) 149.1 (20.8) 149.6 (20.7) 149.5 (21.0) 0.676
DBP (mm Hg) 83.5 (11.1) 83.5 (10.9) 83.0 (11.0) 0.389
Heart rate (bpm) 71.5 (11.1) 71.4 (11.3) 70.7 (10.8) 0.117
Total cholesterol (mg/dL) 209.9 (37.8) 211.2 (39.0) 210.0 (36.2) 0.417
LDL‑C (mg/dL) 129.2 (33.7) 130.0 (34.0) 129.6 (32.7) 0.635
HDL‑C (mg/dL) 53.8 (13.7) 53.6 (13.9) 54.5 (14.3) 0.224
Triglycerides (mg/dL) 137.5 (75.5) 137.6 (75.1) 132.6 (68.6) 0.109
Fasting glucose (mg/dL) 122.9 (41.8) 121.8 (41.8) 120.4 (39.1) 0.268
Energy intake (kcal/d) 2275 (603) 2281 (605) 2272 (605) 0.887
Total fat (g/d) 98.8 (30.3) 99.1 (30.6) 97.8 (29.9) 0.510
Saturated fat (g/d) 25.2 (9.2) 25.5 (9.3) 25.0 (8.9) 0.313
MUFA (g/d) 48.9 (16.0) 49.0 (16.0) 48.6 (16.0) 0.832
PUFA (g/d) 15.8 (6.9) 15.9 (7.2) 15.6 (6.6) 0.380
Proteins (g/d) 92.3 (22.8) 92.6 (23.2) 93.2 (23.5) 0.558
Carbohydrates (g/d) 239.6 (80.6) 239.5 (81.1) 239.9 (81.2) 0.987
Adherence to the MedDiet (points)a 8.6 (2.0) 8.7 (2.0) 8.7 (2.0) 0.037
Alcohol consumption (g/d) 8.3 (14.4) 8.6 (14.1) 8.4 (14.6) 0.718
Physical activity (METs‑min/day) 232 (238) 227 (237) 243 (253) 0.218
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at baseline (Fig.  1). Fasting plasma glucose concentra-
tions were lower in carriers of the G-allele (P value in 
model 1 = 0.009). This association remained statistically 
significant even after additional adjustment for BMI (P 
value in model 2 = 0.014), suggesting independent effects 
of the associations.
Association between the CLOCK‑rs4580704 polymorphism 
and incidence of T2D in non‑T2D subjects: Interaction 
with dietary intervention
We analysed the association between the CLOCK-
rs4580704 polymorphism and incidence of T2D in 
non-T2D subjects at baseline (n = 3671). Table 2 shows 
incidence rates and HR (95  % CI) for T2D varied by 
CLOCK genotype. As carriers of the G-allele presented 
similar incidence rates in the general genetic model, we 
pooled together these subjects (dominant model) and 
estimated T2D risk for G-carriers compared with CC 
homozygotes (reference category). G-allele carriers pre-
sented lower T2D risk than CC homozygous subjects 
(HR: 0.68; 95 % CI 0.54–0.86; P = 0.001). This protective 
association remained statistically significant (HR: 0.69; 
95 % CI 0.54–0.87; P = 0.002) after additional adjustment 
for BMI and the other variables in model 2, suggesting an 
independent effect of CLOCK-rs4580704 polymorphism 
on incident T2D. Additional file  1: Figure S2 shows 
Kaplan–Meier curves for cumulative T2D-free survival 
by CLOCK-rs4580704 genotypes (dominant model) in 
non-T2D subjects over the 4.8  years median follow-up 
period.
When we analysed the modulation of the CLOCK-
rs4580704 polymorphism and incidence of T2D depend-
ing on the dietary intervention, we obtained a P value 
for the interaction term (P = 0.052 in model 2) sugges-
tive such heterogeneity (P < 0.1). Figure 2 shows cumu-
lative T2D-free survival by CLOCK-rs4580704 genotypes 
(dominant model) in non-T2D subjects depending on 
the dietary intervention group [A: MedDiet groups 
(n  =  2477); and B: control group (n  =  1194)]. We 
observed that the protective association of the G-allele 
against T2D incidence was stronger and of higher statis-
tical significance in the MedDiet intervention group (HR: 
0.58; 95  % CI 0.43–0.78; P  <  0.001) than in the control 
group (HR: 0.95; 95 % CI 0.63–1.44; P = 0.818) in model 
2.
Association between the CLOCK‑rs4580704 polymorphism 
and incidence of CVD. Interaction with T2D status 
and modulation by dietary intervention
Additional file 1: Table S3 shows incidence rates of total 
CVD and HR and 95  % CI depending on the CLOCK 
polymorphism (general genetic model) in the whole 
population (T2D and non-TD2 subjects) and stratified by 
T2D. No similar effects were noted for CG and GG and 
the dominant model was not selected for total CVD. We 
Fig. 1 Association between the CLOCK‑rs4580704 SNP and fast‑
ing glucose in non‑T2D subjects at baseline. Means values and SE 
of means (error bars) are represented depending on the CLOCK 
genotypes. The P‑values for the polymorphism were obtained in the 
dominant model for G‑carriers vs CC subjects. P1 Unadjusted model. 
P2 Model adjusted for sex, age, field center and BMI
Table 2 Incidence rate and hazard ratios (HR) for type-2 diabetes (T2D) depending on the CLOCK-rs4580704 in non-T2D 
subjects
Model 1: adjusted for sex, age, center and dietary intervention group
Model 2: adjusted for variables in model 1 plus BMI, drinking, smoking, physical activity, medication (hypertension, dyslipemia and glucose), adherence to the 
Mediterranean Diet and total energy intake at baseline
a Crude incidence rates were expressed per 1000 person-years of follow-up
CLOCK genotypes Non‑T2D subjects at baseline (n = 3671)
Cases Person‑y Incidence ratea Model 1 Model 2
HR 95 % CI P value HR 95 % CI P value
Dominant model
 CC 130 6088.5 21.4 1.00 (Reference) 1.00 (Reference)
 CG + GG 156 10727.7 14.5 0.68 (0.54–0.86) 0.001 0.69 (0.54–0.87) 0.002
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detected a statistically significant interaction between 
T2D status and the CLOCK-rs4580704 SNP (P = 0.019 in 
the multivariable adjusted model 2) on total CVD inci-
dence. The polymorphism was significantly associated 
with CVD incidence in T2D subjects (P = 0.039 in model 
2) and no significant association was detected in non-
T2D subjects (P = 0.649 in model 2). Thus, in the general 
genetic model (CC as reference category), we observed 
protective association between the GG genotype and 
CVD incidence (HR for GG versus CC = 0.48; 95 % CI 
0.27–0.88; P = 0.016) in model 2 for T2D subjects. How-
ever, no significant association was observed for the GG 
genotype in non-T2D subjects (P = 0.370).
On analysing specific causes of CVD (Table  3), we 
obtained a significant interaction between the CLOCK-
rs4580704 SNP and T2D status on stroke incidence (P 
for interaction: 0.018 in the dominant model 2), suggest-
ing more specific effects for this outcome than for myo-
cardial infarction. We observed a significant association 
between the CLOCK polymorphism and stroke in T2D, 
and no significant association was detected for myocar-
dial infarction. For stroke, a protective association was 
observed in T2D G-allele carriers (HR: 0.61; 95  % CI 
0.40–0.94; P = 0.024). Additionally, Additional file 1: Fig-
ure S3 shows cumulative stroke-free survival by CLOCK-
rs4580704 genotypes (three categories) in T2D subjects. 
In non-T2D, the CLOCK SNP was no associated neither 
with stroke (HR: 1.59; 95 % CI 0.83–3–08; P = 0.165 nor 
with myocardial infarction (HR: 0.95; 95 % CI 0.48–1.89; 
P = 0.906).
Finally, we tested the modulation by the dietary 
intervention of the association between the CLOCK-
rs4580704 SNP and stroke in T2D subjects. Additional 
file 1: Table S4 shows detailed information on stroke inci-
dence rates, HR and 95 % CI by genotypes and interven-
tion groups (MedDiet and control groups). Additional 
file 1: Table S3 shows additional information in the two 
MedDiet intervention groups. Although a higher protec-
tive association against stroke is apparent for G-carriers 
in the MedDiet group in comparison with the control 
group, the interaction term between the SNP and diet did 
not reach the statistical significance (P = 0.439 in model 
2) and the heterogeneity by diet is not confirmed.
Discussion
In this longitudinal study, undertaken on 7098 partici-
pants of the PREDIMED trial, we have been able to dem-
onstrate the relevance of the CLOCK-rs4580704 SNP 
in the incidence of T2D and related processes, which 
finally lead to a higher incidence of CVD in T2D sub-
jects, strengthening the connection between genetic 
variants in core clock genes, metabolic alterations and 
CVD risk. In agreement with our results, previous stud-
ies in humans analyzing this or other SNPs in linkage 
disequilibrium (rs1801260, rs3736544, rs4864548 and 
rs3749474) had already reported that the variant allele is 
associated with lower hyperglycemia and prevalence of 
T2D [36, 37]. However, given that cross-sectional studies 
may be confounded by other factors related with obesity 
and other phenotypes concurrently associated with T2D, 
Fig. 2 Cumulative T2D‑free survival by CLOCK‑rs4580704 geno‑
types in non‑T2D subjects at baseline depending on the dietary 
intervention group. a Mediterranean diet groups (n = 2477); and b 
control group (n = 1194). Cox regression models with outcome of 
T2D incidence by the CLOCK‑rs4580704 SNP (CC versus carriers of 
the G‑allele) were multivariable adjusted for each stratum and the 
corresponding hazard ratios (HR) and 95 % CI were obtained in the 
multivariable adjusted models. CC subjects were considered the ref‑
erence category and HR for G‑carriers versus CC were estimated. HR1 
model adjusted for sex, age and field center. HR2 Models additionally 
adjusted for BMI, drinking, smoking, physical activity, medications and 
total energy intake at baseline. P for interaction between the CLOCK 
SNP (as dominant) with dietary intervention (MedDiet vs control 
group) = 0.052 in model 2
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our longitudinal study provides a higher evidence level 
for the contribution of the CLOCK gene to T2D inci-
dence. Moreover, our results are supported by observa-
tions on murine models, given that mice with mutations 
resulting in under-expression of the clock gene presented 
obesity and hyperglycemia [32, 33]. This dual phenotype 
has been a limiting factor in establishing causality as it 
was not possible to tease apart whether the greater risk 
of diabetes in those mice [33] was directly related to the 
functionality of the clock gene or was mediated by obe-
sity. Our study and previous epidemiological studies 
[34–36, 44] show that the CLOCK-rs4580704 SNP was 
also significantly associated with body-weight. However, 
through multivariable adjustment, we have been able to 
show that the associations of the CLOCK-rs4580704 SNP 
with fasting glucose and T2D incidence remain statisti-
cally significant after adjustment for BMI, supporting the 
notion that the observed effect may be additional to that 
of the association with obesity.
Furthermore, we have shown that the association 
between the CLOCK-rs4580704 SNP and T2D incidence 
is modulated by diet. Thus, in the stratified analysis by 
dietary intervention (MedDiet vs control diet), the pro-
tective association between the minor G-allele and T2D 
risk was enhanced in subjects allocated to the MedDiet 
intervention group being highly statistically significant. 
However, no significant protective effect in carriers of the 
G-allele was observed in subjects in the control (low-fat 
diet) group. Although, in our study, the gene-diet inter-
action term between the SNP and dietary intervention 
on T2D incidence was borderline significant (P = 0.052) 
at P  <  0.05, taking into account that we can consider a 
P < 0.1 for the significance level of the interaction term 
as suggestive of interaction when some criteria of reliabil-
ity are accomplished [45], our study fulfill these criteria 
to avoid false negative results and we considered this sig-
nificance level (P < 0.1) to conduct the stratified analyses 
by MedDiet intervention groups. These criteria require 
that [45] the subgroup (dietary intervention) variable 
was measured at baseline and randomly distributed; we 
had an a priori hypothesis of the higher protective effect 
of the variant allele in the MedDiet intervention group 
(high MUFA); the direction of the subgroup effect was 
specified; a small number of hypotheses were tested and 
the size of the interaction effect was large. Our hypoth-
esis of a higher protective effect against T2D of the vari-
ant allele (G) was based on our previous results obtained 
in the GOLDN study [36]. Therefore, our results support 
that the association between the CLOCK-rs4580704 SNP 
and T2D can be modulated by dietary intake, having the 
MedDiet pattern an increasing protective effect of the 
G-allele against the disease.
The dietary modulation of the CLOCK gene expres-
sion effects on metabolic phenotypes has been previously 
shown is animal models [11, 32, 33]. Moreover, in our 
previous study in a US white population we specifically 
reported a gene-diet interaction between the CLOCK-
rs4580704 SNP and the contribution of MUFAs in the diet 
in determining fasting glucose concentrations and insulin 
resistance (HOMA-IR). Hence, when the MUFA intake (% 
Table 3 Incidence rate and hazard ratios (HR) for stroke and myocardial infarction depending on the CLOCK-rs4580704 
in T2D subjects at baseline (n = 3427)
Model 1: adjusted for sex, age, center and dietary intervention group
Model 2: adjusted for variables in model 1 plus BMI, drinking, smoking, physical activity, medication (hypertension, dyslipemia and glucose), adherence to the 
Mediterranean Diet and total energy intake at baseline
P for interaction terms between the CLOCK SNP (as dominant) with T2D in determining stroke or myocardial infarction were estimated in the corresponding 
multivariable models in the whole population
a Crude incidence rates were expressed per 1000 person-years of follow-up
CLOCK genotypes Cases Person‑y Incidence ratea Model 1 Model 2
HR 95 % CI P value HR 95 % CI P value
Stroke
 Dominant model
  CC 43 5780.3 7.4 1.00 (Reference) 1.00 (Reference)
  CG + GG 43 9306.9 4.6 0.61 (0.40–0.93) 0.022 0.61 (0.40–0.94) 0.024
  P (interaction CLOCK × T2D status) 0.016 0.018
Myocardial infraction
 Dominant model
  CC 24 5479.4 4.4 1.00 (Reference) 1.00 (Reference)
  CG + GG 40 9057.8 4.4 0.99 (0.60–1.65) 0.982 1.01 (0.61–1.70) 0.941
  P (interaction CLOCK × T2D status) 0.906 0.922
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of energy) was below the median (<13.2 %), no significant 
differences were found for plasma glucose concentrations 
and HOMA-IR between carriers and non-carriers of the 
G-allele. However, when MUFA intake was high (≥13.2 %), 
G-allele carriers had significantly lower plasma glucose 
concentrations and lower HOMA-IR values than did non-
carriers. The MedDiet is precisely characterized by a high 
contribution of MUFAs (about 20 %), coming mainly from 
olive oil. In the intervention with MedDiet group, the 
MUFA content in the diet was significantly higher than in 
the low fat control group, as we described previously [39]. 
This high MUFA intake in the MedDiet intervention group 
could be one of the factors that may contribute to explain 
the higher protective effect against T2D incidence observed 
for G-carriers in the MedDiet intervention group but not in 
the control group in in agreement with our previous results 
obtained in the cross-sectional study carried out in the US 
population [36]. Furthermore, we can even hypothesize 
that the interaction effect between groups could be even 
higher and more significant if more differences in MUFA 
intake were reached (being a Mediterranean population, 
MUFA intake in the PREDIMED study is generally higher 
than in the US population). Although the mechanisms 
explaining the observed gene-diet modulation on T2D 
remain unknown, recent studies have suggested that DNA 
methylation may be an important mechanism to drive 
circadian clock plasticity [46, 47]. In support of this argu-
ment, we have shown, in Mediterranean subjects [48], that 
the percentage of methylation of certain CpG islands in the 
CLOCK gene were significantly associated with MUFA and 
PUFA intakes, adding preliminary evidence to the potential 
epigenetic dietary modulation, although this requires fur-
ther additional work to be confirmed.
The polymorphism in the CLOCK-rs4580704 gene is 
located in an intron and its function is still unknown. 
However, it involves a tag SNP that is in linkage dis-
equilibrium with other SNPs in the 3’UTR region that 
could be modulated by microRNAs. In our previous 
work focusing on this SNP [36], a specific bioinformatics 
analysis for CLOCK-rs4580704 SNP allowed us to affirm 
that SNP rs4580704 was predicted to produce an allele-
specific CREM (cAMP responsive element modulator) 
binding site (C allele on forward strand binds CREM, G 
allele does not). In this bioinformatics analysis we used 
MAPPER [49] to identify potential allele-specific tran-
scription factor binding sites and RNAfold [50] within 
the Vienna RNA package as previously detailed [36]. 
CREM has been shown to be responsible for circadian 
expression in the mouse of many genes that could also be 
implicated in T2D and CVD risk [51–53]. Either by itself, 
or as an indicator of another functional SNP, the vari-
ant G-allele of the CLOCK-rs4580704 SNP in our study 
is associated with lower fasting glucose concentrations 
in non-diabetics, lower T2D incidence and less CVD 
risk in T2D subjects. Bearing in mind that in murine 
clock mutant models [11, 32, 33], the reduction in clock 
gene expression is precisely associated with an opposite 
phenotype characterized by hyperglycemia, hyperinsu-
linemia and metabolic syndrome and considering that 
β cell clock gene ablation in mice caused severe glucose 
intolerance [10], the minor CLOCK-rs4580704 G-allele 
in humans would be associated with a higher conser-
vation of gene functionality, i.e. in this case it would 
be the major allele which would provoke a situation of 
higher vulnerability to circadian adaptation and higher 
likelihood of chronodisruption. Carriers of the variant 
G-allele would be subjects that could better adapt to cir-
cadian disruption (i.e., deficient sleep, inadequate time of 
meals, shift work), or who maintain their rhythmicity of 
its processes with less alterations, presenting greater pro-
tection against obesity, T2D and future CVD.
Other SNPs in core circadian genes, such as BMAL1, 
that forms a complex with CLOCK, have been associ-
ated with T2D prevalence in some human studies and 
in murine models [11, 32, 54, 55] reinforcing the con-
tribution of the circadian system to the etiology of T2D; 
however, no human study has reported an association 
between SNPs in core circadian genes and incidence of 
stroke as demonstrated in the current study. It is interest-
ing to note that the association of the CLOCK-rs4580704 
SNPs with stroke was only present in T2D subjects. 
This is compatible with a higher chronodisruption in 
these subjects, resulting in a higher CVD risk in a rela-
tively short follow-up period (median follow-up approx. 
5 years). Circadian variations in relevant risk factors for 
CVD such as insulin sensitivity, blood pressure, renal 
function, heart rate, platelet aggregability, fibrinolytic 
markers and levels, hormone concentrations etc. [9, 16, 
17, 56–58] may explain the morning onset of myocardial 
infarction, stroke and other CVD clinical events [17, 18, 
23]. These circadian variations may be more important 
in T2D patients and their dysregulation contributing to 
a higher CVD (mainly stroke) incidence in more suscep-
tible individuals such as CLOCK-rs4580704 CC homozy-
gous subjects (for whom our results suggest a lower 
flexibility). Although it is well known that T2D subjects 
have higher CVD risk than non-diabetic subjects [7, 8], 
a great heterogeneity has been described [59]. This het-
erogeneity in CVD risk is only partially understood but 
is a key consideration for our understanding of the nexus 
of T2D and CVD and for the development of individu-
alized CVD risk reduction strategies. According to our 
results, we suggest circadian alterations due to functional 
genetic variants in core clock genes such as CLOCK as 
another factor that may contribute to this heterogeneity 
and higher risk of CVD (mainly, stroke) in those subjects. 
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As measuring the processes of circadian dysregulation is 
complex, the CLOCK-rs4580704 SNP can be considered 
as a proxy for higher chronodisruption risk in CC sub-
jects. Thus, this SNP will be of interest as an instrumen-
tal variant in future Mendelian Randomization in other 
cohorts analyzing CVD risk in T2D subjects.
Conclusions
In conclusion, we have described for the first time an 
association between the CLOCK-rs4580704 SNP and 
incidence of T2D. These results are in agreement with 
previous knowledge obtained from animal and human 
cross-sectional studies. In addition we have found that 
this association with T2D can be modulated by dietary 
intake in the framework of a randomized controlled 
trial, with the MedDiet increasing the protective effects 
of the G-allele against T2D. Moreover, we have extended 
our finding also showing a novel association between the 
G-allele and protection against stroke in T2D subjects. 
Although our results highlight the contribution of the 
circadian system both on the incidence of T2D and CVD 
risk in T2D subjects it is presumable that the functional 
effects of CLOCK gene could be either circadian rhythm-
dependent or independent. In the present study, as 
there is no assessments regarding the circadian rhythm 
of the study subjects, the suggested link between the 
CLOCK SNP and chronodisruption remains speculative, 
and more studies are needed to reveal the mechanisms 
behind these epidemiological associations.
Authors’ contributions
DC conceived the study concept and design, obtained funding, acquired 
data, analyzed and interpreted data, wrote the manuscript, and reviewed/
edited the manuscript. EMA acquired data, analyzed and interpreted data 
and reviewed/edited the manuscript. OC designed and developed the data 
management system, analyzed and interpreted data, wrote the manuscript 
and elaborated tables and figures, and reviewed/edited the manuscript. JVS 
conceived the study concept, acquired data, analyzed and interpreted data, 
and reviewed/edited the manuscript. RE conceived the study concept and 
design, obtained funding, acquired data, analyzed and interpreted data, and 
reviewed the manuscript. MAMG conceived the study concept and design, 
obtained funding and reviewed/edited the manuscript. JSS conceived the 
study concept and design, obtained funding and reviewed the manuscript. 
MF obtained funding and reviewed the manuscript. FA conceived the study 
concept and design, obtained funding and reviewed the manuscript. JL 
Additional file
Additional file 1: Figure S1. Flow‑chart. Figure S2. Cumulative T2D‑
free survival by CLOCK‑rs4580704 genotypes depending on the dietary 
intervention group. Figure S3. Cumulative stroke‑free survival by CLOCK‑
rs4580704 genotypes. Table S1. Characteristics of the PREDIMED study 
participants at baseline according to the dietary intervention groups. 
Table S2. Characteristics of the PREDIMED study participants at baseline 
according to the T2D status. Table S3. Incidence rate and hazard ratios 
(HR) for total cardiovascular diseases (CVD) depending on the CLOCK‑
rs4580704. Table S4. Incidence rate and hazard ratios (HR) for stroke 
depending on the CLOCK‑rs4580704 in T2D subjects and stratified by 
dietary intervention.
conceived the study concept and design, obtained funding and reviewed the 
manuscript. LLSM conceived the study concept and design, obtained funding 
and reviewed the manuscript. EGG conceived the study concept and design, 
obtained funding and reviewed the manuscript. COA performed the experi‑
ments, acquired data and reviewed/edited the manuscript MF conceived the 
study concept and design, obtained funding and reviewed the manuscript. 
JDE acquired data and reviewed the manuscript. AD acquired data and 
reviewed the manuscript. OCR acquired data and reviewed the manuscript. 
ER conceived the study concept and design, obtained funding, interpreted 
data, and reviewed/edited the manuscript. JMO conceived the study concept 
and design, obtained funding, interpreted data, wrote the manuscript, and 
reviewed/edited the manuscript. DC is the guarantor of this work and, such, 
had full access to all the data in the study and takes responsibility for the 
integrity of the data and the accuracy of the data analysis. All authors read and 
approved the final manuscript.
Author details
1 Department of Preventive Medicine and Public Health, Genetic and Molecu‑
lar Epidemiology Unit, School of Medicine, University of Valencia, Blasco 
Ibañez, 15, 46010 Valencia, Spain. 2 CIBER Fisiopatología de la Obesidad y 
Nutrición, Instituto de Salud Carlos III, Madrid, Spain. 3 Department of Com‑
puter Languages and Systems, School of Technology and Experimental Sci‑
ences, Universitat Jaume I, Castellón, Spain. 4 Department of Internal Medicine, 
Hospital Clinic, IDIBAPS, Barcelona, Spain. 5 The PREDIMED (Prevención con 
Dieta Mediterránea) Research Network (RD 06/0045), Instituto de Salud Carlos 
III (ISCIII), Madrid, Spain. 6 Department of Preventive Medicine and Public 
Health, University of Navarra, Pamplona, Navarra, Spain. 7 Human Nutrition 
Unit, Biochemistry and Biotechnology Department, Faculty of Medicine 
and Health Sciences, IISPV, University Rovira i Virgili, Reus, Spain. 8 Cardiovas‑
cular Risk and Nutrition Unit, Hospital del Mar Institut for Medical Research 
(IMIM), Barcelona, Spain. 9 Department of Cardiology, University Hospital 
of Araba, Vitoria, Spain. 10 Department of Family Medicine, Research Unit, 
Distrito Sanitario Atención Primaria Sevilla, Seville, Spain. 11 Research Institute 
of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, 
Las Palmas de Gran Canaria, Spain. 12 Department of Epidemiology, School 
of Medicine, University of Malaga, Malaga, Spain. 13 Palma Institute of Health 
Research (IdISPa), Hospital Son Espases, Palma de Mallorca, Spain. 14 Atención 
Primaria, Servicio Navarro de Salud‑Osasunbidea, Pamplona, Navarra, Spain. 
15 Navarra Institute for Health Research (IdiSNA), Pamplona, Navarra, Spain. 
16 Lipid Clinic, Endocrinology and Nutrition Service, Institut d’Investigacions 
Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, Barcelona, Spain. 
17 Department of Cardiovascular Epidemiology and Population Genetics, 
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain. 
18 IMDEA Alimentación, Madrid, Spain. 19 Nutrition and Genomics Labora‑
tory, JM‑USDA Human Nutrition Research Center on Aging at Tufts University, 
Boston, MA, USA. 
Competing interests
JS.‑S. is a nonpaid member of the Scientific Advisory Board of the International 
Nut Council and E. R. and is a nonpaid member of the California Walnut Com‑
mission Scientific Advisory Committee. The other authors have no conflicts of 
interest. None of the funding sources played a role in the design, collection, 
analysis, or interpretation of the data or in the decision to submit the manu‑
script for publication.
Funding
This study was funded, by the Spanish Ministry of Health (Instituto de Salud 
Carlos III) and the Ministerio de Economía y Competitividad (Projects PI051839, 
PI070240, PI1001407, G03/140, CIBER 06/03, RD06/0045 PI07‑0954, CNIC‑06, 
PI11/02505, SAF2009‑12304, AGL2010‑22319‑C03‑03 and PRX14/00527), 
Fondo Europeo de Desarrollo Regional, by the University Jaume I (Project 
P1‑1B2013‑54) and by the Generalitat Valenciana (AP111/10, AP‑042/11, 
BEST/2015/087, GVACOMP2011‑151, ACOMP/2011/145, ACOMP/2012/190 
and ACOMP/2013/159). This material is based upon work supported by the 
U.S. Department of Agriculture—Agricultural Research Service (ARS), under 
Agreement No. 58‑1950‑4‑003.
Received: 21 November 2015   Accepted: 29 December 2015
Page 11 of 12Corella et al. Cardiovasc Diabetol  (2016) 15:4 
References
 1. Nathan DM. Diabetes: advances in diagnosis and treatment. JAMA. 
2015;314:1052–62.
 2. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiol‑
ogy, biological mechanisms, treatment recommendations and future 
research. World J Diabetes. 2015;6:1246–58.
 3. Pandey A, Chawla S, Guchhait P. Type‑2 diabetes: current understanding 
and future perspectives. IUBMB Life. 2015;67:506–13.
 4. Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with 
diabetes. Nutr Metab Cardiovasc Dis. 2010;20:474–80.
 5. Masrur S, Cox M, Bhatt DL, Smith EE, Ellrodt G, Fonarow GC, et al. Associa‑
tion of acute and chronic hyperglycemia with acute ischemic stroke out‑
comes post‑thrombolysis: findings from get with the guidelines‑stroke. J 
Am Heart Assoc. 2015;4:e002193.
 6. Ogedengbe OS, Ezeani IU, Chukwuonye II, Anyabolu EN, Ozor II, Eregie A. 
Evaluating the impact of type 2 diabetes mellitus on cardiovascular risk in 
persons with metabolic syndrome using the UKPDS risk engine. Diabetes 
Metab Syndr Obes. 2015;8:437–45.
 7. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact 
of diabetes on cardiovascular disease risk and all‑cause mortality in older 
men: influence of age at onset, diabetes duration, and established and 
novel risk factors. Arch Intern Med. 2011;171:404–10.
 8. Collaboration Emerging Risk Factors, Sarwar N, Gao P, Seshasai SR, Gobin 
R, Kaptoge S, et al. Diabetes mellitus, fasting blood glucose concentra‑
tion, and risk of vascular disease: a collaborative meta‑analysis of 102 
prospective studies. Lancet. 2010;375:2215–22.
 9. Eckel RH, Depner CM, Perreault L, Markwald RR, Smith MR, McHill AW, 
et al. Morning circadian misalignment during short sleep duration 
impacts insulin sensitivity. Curr Biol. 2015;25:3004–10.
 10. Perelis M, Marcheva B, Ramsey KM, Schipma MJ, Hutchison AL, Taguchi A, 
et al. Pancreatic β cell enhancers regulate rhythmic transcription of genes 
controlling insulin secretion. Science. 2015;350:aac4250.
 11. Marcheva B, Ramsey KM, Buhr ED, Kobayashi Y, Su H, Ko CH, et al. Disrup‑
tion of the clock components CLOCK and BMAL1 leads to hypoinsulinae‑
mia and diabetes. Nature. 2010;466:627–31.
 12. Tan E, Scott EM. Circadian rhythms, insulin action, and glucose homeosta‑
sis. Curr Opin Clin Nutr Metab Care. 2014;17:343–8.
 13. Gerhart‑Hines Z, Lazar MA. Circadian metabolism in the light of evolution. 
Endocr Rev. 2015;36:289–304.
 14. Partch CL, Green CB, Takahashi JS. Molecular architecture of the mam‑
malian circadian clock. Trends Cell Biol. 2014;24:90–9.
 15. Delezie J, Challet E. Interactions between metabolism and circadian 
clocks: reciprocal disturbances. Ann Acad Sci. 2011;1243:30–46.
 16. Maury E, Ramsey KM, Bass J. Circadian rhythms and metabolic syndrome: 
from experimental genetics to human disease. Circ Res. 2010;106:447–62.
 17. Takeda N, Maemura K. The role of clock genes and circadian rhythm 
in the development of cardiovascular diseases. Cell Mol Life Sci. 
2015;72:3225–34.
 18. Caliskan M, Caliskan Z, Gullu H, Keles N, Bulur S, Turan Y, et al. Increased 
morning blood pressure surge and coronary microvascular dysfunction in 
patient with early stage hypertension. J Am Soc Hypertens. 2014;8:652–9.
 19. Sheppard JP, Hodgkinson J, Riley R, Martin U, Bayliss S, McManus RJ. 
Prognostic significance of the morning blood pressure surge in clinical 
practice: a systematic review. J Hypertens. 2015;28:30–41.
 20. Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, et al. Cir‑
cadian variation in the frequency of onset of acute myocardial infarction. 
N Engl J Med. 1985;313:1315–22.
 21. Tofler GH, Muller JE, Stone PH, Forman S, Solomon RE, Knatterud GL, 
Braunwald E. Modifiers of timing and possible triggers of acute myocar‑
dial infarction in the Thrombolysis in Myocardial Infarction Phase II (TIMI 
II) Study Group. J Am Coll Cardiol. 1992;20:1049–55.
 22. Vitale J, Manfredini R, Gallerani M, Mumoli N, Eagle KA, Ageno W, 
Dentali F. Chronobiology of acute aortic rupture or dissection: a 
systematic review and a meta‑analysis of the literature. Chronobiol Int. 
2015;32:385–94.
 23. Marsh EE 3rd, Biller J, Adams HP Jr, Marler JR, Hulbert JR, Love BB, Gordon 
DL. Circadian variation in onset of acute ischemic stroke. Arch Neurol. 
1990;47:1178–80.
 24. Gan Y, Yang C, Tong X, Sun H, Cong Y, Yin X, et al. Shift work and diabetes 
mellitus: a meta‑analysis of observational studies. Occup Environ Med. 
2015;72:72–8.
 25. Buchvold HV, Pallesen S, Øyane NM, Bjorvatn B. Associations between 
night work and BMI, alcohol, smoking, caffeine and exercise–a cross‑
sectional study. BMC Public Health. 2015;15:1112.
 26. Brum MC, Filho FF, Schnorr CC, Bottega GB, Rodrigues TC. Shift work and 
its association with metabolic disorders. Diabetol Metab Syndr. 2015;7:45.
 27. Vetter C, Fischer D, Matera JL, Roenneberg T. Aligning work and circadian 
time in shift workers improves sleep and reduces circadian disruption. 
Curr Biol. 2015;25:907–11.
 28. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and 
cardiovascular consequences of circadian misalignment. Proc Natl Acad 
Sci USA. 2009;106:4453–8.
 29. Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral 
clocks. Nat Rev Neurosci. 2001;2:521–6.
 30. Ko CH, Takahashi JS. Molecular components of the mammalian circadian 
clock. Hum Mol Genet. 2006;15:R271–7.
 31. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald 
JD, et al. Mutagenesis and mapping of a mouse gene, Clock, essential for 
circadian behavior. Science. 1994;264:719–25.
 32. Rudic RD, McNamara P, Curtis AM, Boston RC, Panda S, Hogenesch JB, 
Fitzgerald GA. BMAL1 and CLOCK, two essential components of the circa‑
dian clock, are involved in glucose homeostasis. PLoS Biol. 2004;2:e377.
 33. Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E, et al. Obe‑
sity and metabolic syndrome in circadian Clock mutant mice. Science. 
2005;308:1043–5.
 34. Scott EM, Carter AM, Grant PJ. Association between polymorphisms in 
the Clock gene, obesity and the metabolic syndrome in man. Int J Obes 
(Lond). 2008;32:658–62.
 35. Sookoian S, Gemma C, Gianotti TF, Burgueño A, Castaño G, Pirola CJ. 
Genetic variants of Clock transcription factor are associated with indi‑
vidual susceptibility to obesity. Am J Clin Nutr. 2008;87:1606–15.
 36. Garaulet M, Lee YC, Shen J, Parnell LD, Arnett DK, Tsai MY, et al. CLOCK 
genetic variation and metabolic syndrome risk: modulation by monoun‑
saturated fatty acids. Am J Clin Nutr. 2009;90:1466–75.
 37. Uemura H, Katsuura‑Kamano S, Yamaguchi M, Arisawa K, Hamajima N, 
Hishida A, et al. A variant of the CLOCK gene and related haplotypes 
are associated with the prevalence of type 2 diabetes in the Japanese 
population. J Diabetes. 2015. doi:10.1111/1753‑0407.12344.
 38. Martínez‑González MÁ, Corella D, Salas‑Salvadó J, Ros E, Covas MI, Fiol M, 
et al. Cohort profile: design and methods of the PREDIMED study. Int J 
Epidemiol. 2012;41:377–85.
 39. Estruch R, Ros E, Salas‑Salvadó J, Covas MI, Corella D, Arós F, et al. Primary 
prevention of cardiovascular disease with a Mediterranean diet. N Engl J 
Med. 2013;368:1279–90.
 40. Fernández‑Ballart JD, Piñol JL, Zazpe I, Corella D, Carrasco P, Toledo E, 
et al. Relative validity of a semi‑quantitative food‑frequency ques‑
tionnaire in an elderly Mediterranean population of Spain. Br J Nutr. 
2010;103:1808–16.
 41. Schröder H, Fitó M, Estruch R, Martínez‑González MA, Corella D, Salas‑
Salvadó J, et al. A short screener is valid for assessing Mediterranean diet 
adherence among older Spanish men and women. J Nutr. 2011;141:1140–5.
 42. Estruch R, Martínez‑González MA, Corella D, Salas‑Salvadó J, Ruiz‑Gutiér‑
rez V, Covas MI, et al. Effects of a Mediterranean‑style diet on cardiovascu‑
lar risk factors: a randomized trial. Ann Intern Med. 2006;145:1–11.
 43. Salas‑Salvadó J, Bulló M, Estruch R, Ros E, Covas MI, Ibarrola‑Jurado N, 
et al. Prevention of diabetes with Mediterranean diets: a subgroup analy‑
sis of a randomized trial. Ann Intern Med. 2014;160:1–10.
 44. Valladares M, Obregón AM, Chaput JP. Association between genetic vari‑
ants of the clock gene and obesity and sleep duration. J Physiol Biochem. 
2015;71:855–60.
 45. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? 
Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 
2010;340:c117.
 46. Azzi A, Dallmann R, Casserly A, Rehrauer H, Patrignani A, Maier B, et al. 
Circadian behavior is light‑reprogrammed by plastic DNA methylation. 
Nat Neurosci. 2014;17:377–82.
 47. Welberg L. Circadian rhythms: Methylation mediates clock plasticity. Nat 
Rev Neurosci. 2014;15:206–7.
 48. Milagro FI, Gómez‑Abellán P, Campión J, Martínez JA, Ordovás JM, 
Garaulet M. CLOCK, PER2 and BMAL1 DNA methylation: association with 
obesity and metabolic syndrome characteristics and monounsaturated 
fat intake. Chronobiol Int. 2012;29:1180–94.
Page 12 of 12Corella et al. Cardiovasc Diabetol  (2016) 15:4 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 49. Marinescu VD, Kohane IS, Riva A. MAPPER: a search engine for the com‑
putational identification of putative transcription factor binding sites in 
multiple genomes. BMC Bioinform. 2005;6:79.
 50. Gruber AR, Lorenz R, Bernhart SH, Neuböck R, Hofacker IL. The Vienna 
RNAwebsuite. Nucleic Acids Res. 2008;36:W70–4.
 51. Hughes ME, DiTacchio L, Hayes KR, Vollmers C, Pulivarthy S, Baggs JE, 
et al. Harmonics of circadian gene transcription in mammals. PLoS Genet. 
2009;5:e1000442.
 52. Seidl MD, Steingräber AK, Wolf CT, Sur TM, Hildebrandt I, Witten A, et al. 
Transcription factor cAMP response element modulator (Crem) restrains 
Pdgf‑dependent proliferation of vascular smooth muscle cells in mice. 
Pflugers Arch. 2015;467:2165–77.
 53. Bitar MS, Al‑Mulla F. Upregulation of CREM/ICER suppresses wound 
endothelial CRE‑HIF‑1α‑VEGF‑dependent signaling and impairs angio‑
genesis in type 2 diabetes. Dis Model Mech. 2015;8:65–80.
 54. Lee J, Kim MS, Li R, Liu VY, Fu L, Moore DD, et al. Loss of Bmal1 leads to 
uncoupling and impaired glucose‑stimulated insulin secretion in β‑cells. 
Islets. 2011;3:381–8.
 55. Woon PY, Kaisaki PJ, Bragança J, Bihoreau MT, Levy JC, Farrall M, et al. Aryl 
hydrocarbon receptor nuclear translocator‑like (BMAL1) is associated 
with susceptibility to hypertension and type 2 diabetes. Proc Natl Acad 
Sci USA. 2007;104:14412–7.
 56. Solocinski K, Gumz ML. The circadian clock in the regulation of renal 
rhythms. J Biol Rhythms. 2015;30:470–86.
 57. Scheer FA, Shea SA. Human circadian system causes a morning peak in 
prothrombotic plasminogen activator inhibitor‑1 (PAI‑1) independent of 
the sleep/wake cycle. Blood. 2014;123:590–3.
 58. Challet E. Keeping circadian time with hormones. Diabetes Obes Metab. 
2015;17(S1):76–83.
 59. Gore MO, McGuire DK, Lingvay I, Rosenstock J. Predicting cardiovascular 
risk in type 2 diabetes: the heterogeneity challenges. Curr Cardiol Rep. 
2015;17:607.
